The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study.
Gunnar Folprecht
Consultant or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Roche/Genentech
Honoraria - Amgen; Merck KGaA; Roche
Research Funding - Merck KGaA; Pfizer; Sanofi
Thomas Gruenberger
No relevant relationships to disclose
Wolf Bechstein
No relevant relationships to disclose
Florian Lordick
No relevant relationships to disclose
Hauke Lang
No relevant relationships to disclose
J├╝rgen Weitz
No relevant relationships to disclose
Thomas Suedhoff
No relevant relationships to disclose
Joerg Thomas Hartmann
No relevant relationships to disclose
Torsten Liersch
No relevant relationships to disclose
Claus-Henning Kohne
No relevant relationships to disclose